Casdin Capital's latest 13F filing for the third quarter of 2026 reveals a total portfolio value of $2.30 billion, a notable increase from the previous quarter. The firm, known for its focus on the life sciences and biotechnology sectors, maintains a concentrated portfolio with its top eight holdings accounting for a significant portion of its assets. The largest positions remain in Revolution Medicines (RVMD), Relay Therapeutics (RLAY), and GeneDx Holdings (WGS), with their respective portfolio weights increasing to 23.04%, 12.61%, and 11.68%.
The filing highlights several material changes in the portfolio. Casdin initiated new positions in Tempus AI (TEM) and Oric Pharmaceuticals (ORIC), signaling new areas of interest within the healthcare technology and oncology landscapes. The firm also significantly increased its stake in Sarepta Therapeutics (SRPT), a high-signal addition, more than tripling its share count. Other notable additions include increased investments in Grail (GRAL) and Beam Therapeutics (BEAM), further deepening the firm's commitment to innovative biotech companies.
Conversely, Casdin exited its position in Sionna Therapeutics, a high-signal change indicating a complete divestment from the company. The firm also trimmed its holdings in several other companies, including GPCR Therapeutics and Denali Therapeutics, suggesting a strategic reallocation of capital. These adjustments reflect an active management approach, concentrating capital in high-conviction names while opportunistically entering new ventures and exiting others.